Abstract
Survivin is a relatively unique member of the inhibitor of apoptosis protein (IAP) family. It contains a single baculovirus IAP repeat (BIR) domain. It is involved in the control of cell cycle and inhibition of apoptosis. Survivin is of interest because it is specifically up-regulated in cancer cells and completely down-regulated and undetectable in normal adult tissues. Thus, survivin has proved to be a promising therapeutic target for normal anti-cancer therapy. Survivin protects the fast dividing tumor cells against default apoptosis to facilitate aberrant mitosis. Down-regulation of survivin with multiple approaches, suppress tumor progression and induce apoptosis on its own or in combination with chemotherapy and radiotherapy.
Keywords: Survivin, IAPs, Apoptosis, Caspases, Ribozyme, p53
Current Cancer Therapy Reviews
Title: Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene
Volume: 2 Issue: 1
Author(s): Zakir Khan, Pratiksha Bhadouria, Radha Gupta and Prakash S. Bisen
Affiliation:
Keywords: Survivin, IAPs, Apoptosis, Caspases, Ribozyme, p53
Abstract: Survivin is a relatively unique member of the inhibitor of apoptosis protein (IAP) family. It contains a single baculovirus IAP repeat (BIR) domain. It is involved in the control of cell cycle and inhibition of apoptosis. Survivin is of interest because it is specifically up-regulated in cancer cells and completely down-regulated and undetectable in normal adult tissues. Thus, survivin has proved to be a promising therapeutic target for normal anti-cancer therapy. Survivin protects the fast dividing tumor cells against default apoptosis to facilitate aberrant mitosis. Down-regulation of survivin with multiple approaches, suppress tumor progression and induce apoptosis on its own or in combination with chemotherapy and radiotherapy.
Export Options
About this article
Cite this article as:
Khan Zakir, Bhadouria Pratiksha, Gupta Radha and Bisen S. Prakash, Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene, Current Cancer Therapy Reviews 2006; 2 (1) . https://dx.doi.org/10.2174/157339406777592113
DOI https://dx.doi.org/10.2174/157339406777592113 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Characterization of Histone Deacetylase Inhibitor and Tumor Cell-Growth Inhibition Properties of New Benzofuranone Compounds
Current Cancer Drug Targets The Role of Mesothelin in Tumor Progression and Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry Is the Vascular System a Main Target for Thyroid Hormones? From Molecular and Biochemical Findings to Clinical Perspectives
Current Vascular Pharmacology Biomarkers of Protein Oxidation in Human Disease
Current Molecular Medicine HGF-Antagonists: Structure, Activities, and Anti-cancer Approach
Current Signal Transduction Therapy The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Folate Targeted Solid Lipid Nanoparticles of Simvastatin for Enhanced Cytotoxic Effects of Doxorubicin in Chronic Myeloid Leukemia
Current Nanoscience A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry Current Status and Future Perspectives on Old Drug Repurposing for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Folic Acid Conjugated Chitosan Nanoparticles for Tumor Targeting of Therapeutic and Imaging Agents
Pharmaceutical Nanotechnology Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Current Cancer Therapy Reviews Acrylamide Induced Toxicity and the Propensity of Phytochemicals in Amelioration: A Review
Central Nervous System Agents in Medicinal Chemistry Mini-Review: Nucleus-Targeted Ribonucleases As Antitumor Drugs
Current Medicinal Chemistry Toward The Rational Design of Cell Fate Modifiers Notch Signaling as a Target for Novel Biopharmaceuticals
Current Pharmaceutical Biotechnology The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Recent Advancements in Carbon Nanofiber and Carbon Nanotube Applications in Drug Delivery and Tissue Engineering
Current Pharmaceutical Design Epidemiology, Clinical Presentation and Treatment of Uveal Melanoma
Clinical Cancer Drugs P68 RNA Helicase (DDX5) Required for the Formation of Various Specific and Mature miRNA Active RISC Complexes
MicroRNA